Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Garnett

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
British Journal of Clinical Pharmacology|January 3, 2013
Early QT assessment--how can our confidence in the data be improved?Borje Darpo, Christine Garnett
Drug Safety|February 21, 2014
Impact of electrocardiographic data quality on moxifloxacin response in thorough QT/QTc studiesLars Johannesen, Christine Garnett, Marek Malik
Journal of Pharmacokinetics and Pharmacodynamics|June 25, 2025
FDA's insights: implementing new strategies for evaluating drug-induced QTc prolongationYanyan Ji, Lars Johannesen, Christine Garnett
Drug Safety|February 21, 2014
Electrocardiographic data quality in thorough QT/QTc studiesLars Johannesen, Christine Garnett, Marek Malik
CPT: Pharmacometrics & Systems Pharmacology|May 3, 2019
Quantitative Systems Pharmacology Models for a New International Cardiac Safety Regulatory Paradigm: An Overview of the Comprehensive In Vitro Proarrhythmia Assay In Silico Modeling ApproachZhihua Li, Christine Garnett, David G Strauss
Clinical Pharmacology and Therapeutics|October 19, 2019
Redefining Blood Pressure Assessment - The Role of the Ambulatory Blood Pressure Monitoring Study for Drug SafetyChristine Garnett, Lars Johannesen, Tzu-Yun McDowell
Journal of Electrocardiology|September 25, 2012
Practice and challenges of thorough QT studiesNorman Stockbridge, Joanne Zhang, Christine Garnett, et al.
Drug Safety|July 12, 2015
Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14Borje Darpo, Christine Garnett, James Keirns, et al.
Drug Safety|February 19, 2013
Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated?Norman Stockbridge, Joel Morganroth, Rashmi R Shah, et al.
Journal of Clinical Pharmacology|February 9, 2018
Study Design Parameters Affecting Exposure Response Analysis of QT Data: Results From Simulation StudiesGeorg Ferber, Yaning Sun, Borje Darpo, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
British Journal of Clinical Pharmacology|January 3, 2013
Early QT assessment--how can our confidence in the data be improved?Borje Darpo, Christine Garnett
Drug Safety|February 21, 2014
Impact of electrocardiographic data quality on moxifloxacin response in thorough QT/QTc studiesLars Johannesen, Christine Garnett, Marek Malik
Journal of Pharmacokinetics and Pharmacodynamics|June 25, 2025
FDA's insights: implementing new strategies for evaluating drug-induced QTc prolongationYanyan Ji, Lars Johannesen, Christine Garnett
Drug Safety|February 21, 2014
Electrocardiographic data quality in thorough QT/QTc studiesLars Johannesen, Christine Garnett, Marek Malik
CPT: Pharmacometrics & Systems Pharmacology|May 3, 2019
Quantitative Systems Pharmacology Models for a New International Cardiac Safety Regulatory Paradigm: An Overview of the Comprehensive In Vitro Proarrhythmia Assay In Silico Modeling ApproachZhihua Li, Christine Garnett, David G Strauss
Clinical Pharmacology and Therapeutics|October 19, 2019
Redefining Blood Pressure Assessment - The Role of the Ambulatory Blood Pressure Monitoring Study for Drug SafetyChristine Garnett, Lars Johannesen, Tzu-Yun McDowell
Journal of Electrocardiology|September 25, 2012
Practice and challenges of thorough QT studiesNorman Stockbridge, Joanne Zhang, Christine Garnett, et al.
Drug Safety|July 12, 2015
Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14Borje Darpo, Christine Garnett, James Keirns, et al.
Drug Safety|February 19, 2013
Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated?Norman Stockbridge, Joel Morganroth, Rashmi R Shah, et al.
Journal of Clinical Pharmacology|February 9, 2018
Study Design Parameters Affecting Exposure Response Analysis of QT Data: Results From Simulation StudiesGeorg Ferber, Yaning Sun, Borje Darpo, et al.
Pageof 4